Kåre Schultz is a Danish business executive, born May 21, 1961, best known as the former President and CEO of Teva Pharmaceutical Industries (2017–2022/23) and prior CEO of H. Lundbeck. As of June 2026, publicly available estimates place his net worth in the range of roughly $28 million to $53 million, based primarily on documented equity holdings in publicly traded companies.
Kåre Schultz Net Worth: Sources, Estimate, and How It’s Derived
Marcus Rothstein
7 Jun 2026
The honest caveat: these figures are derived from SEC insider filings and reported share positions, not a full personal balance sheet, so they almost certainly undercount his total wealth. If you are comparing this executive net worth profile to other celebrity-style songwriter figures, a separate breakdown for Don Schultz songwriter net worth is often discussed in the same wealth-estimation context.
Which Kåre Schultz is this, and how to confirm
There is one Kåre Schultz who stands out clearly in public business records, and the identity trail is unusually well-documented. He is a Danish national, born May 21, 1961, who earned a cand. polit. degree from the University of Copenhagen in 1987.
His spouse is Marianne Schultz. He has held CEO-level roles at two major pharmaceutical companies (Lundbeck and Teva) and currently serves on the boards of Azelis (as Chair), Hims & Hers Health, and SAS (as Chairman). SEC filings, including Form 4 disclosures signed under his name, SEC 8-K appointment filings from Hims & Hers identifying him as age 63 at the time of his July 2024 appointment, and Teva's DEF 14A proxy statements all consistently point to this single individual.
If you come across references to a Kåre Schultz in a different context, say, a Danish academic or a private-sector professional outside pharmaceuticals and life sciences, that is a different person. The Kåre Schultz documented in SEC filings, Azelis corporate governance pages, and SAS board announcements is definitively the one this profile covers. The age (born 1961), nationality (Danish), educational background (University of Copenhagen), and career timeline are the fastest disambiguation signals to check.
What 'net worth' means and how these estimates get built
Net worth, in the simplest sense, is total assets minus total liabilities. For a private individual like Schultz, nobody has access to his bank accounts, real estate portfolio, private investments, or personal liabilities. What financial aggregators and researchers like Benzinga, QuiverQuant, and GuruFocus actually do is something narrower: they pull SEC insider ownership filings, count the publicly reported shares held across named companies, multiply those by current market prices, and call it a net worth estimate. That is a useful starting point, but it is not the same thing as a full financial picture.
The components that feed a well-constructed estimate for an executive like Schultz include: disclosed equity holdings in public companies (from Form 4 filings and proxy statements), historical compensation as documented in DEF 14A filings (salary, bonus targets, and equity grant values), and directorship remuneration disclosed in annual reports like the Azelis Integrated Report. What stays invisible are private assets, real estate not disclosed in public filings, offshore structures, private equity stakes, and accumulated savings from decades of senior executive pay. This is why any published figure should be treated as a documented-equity floor, not a ceiling.
Career overview and the income signals that matter
Schultz's career is the kind of trajectory that generates substantial wealth quietly over time. He rose through senior finance and strategy roles at Novo Nordisk before becoming CFO and later COO there, then moved to CEO of H. Lundbeck, a Copenhagen-based pharmaceutical company. His most financially significant posting was as President and CEO of Teva Pharmaceutical Industries, one of the world's largest generic drug makers, from September 2017 through late 2022 (with his formal departure confirmed into 2023 per Azelis corporate records).
Teva's DEF 14A proxy filings document his compensation structure during that CEO tenure in specific terms: an annual base salary of $2 million, a target annual incentive of 140% of base salary (with a maximum of 200%), and a long-term equity incentive with a target grant-date fair value of $10 million, of which 70% was performance-based. Running the numbers on the target package alone, a single year at Teva represented roughly $14. 8 million in targeted total direct compensation.
Across a five-plus-year CEO run, even accounting for performance variability and equity vesting timelines, the cumulative compensation would be substantial. Additionally, a housing reimbursement was documented with specific exchange-rate assumptions (3. 35 shekels per U. S.
dollar for 2022 averages), which illustrates the international structure of his pay.
Since stepping down from the Teva CEO role, Schultz has transitioned into a portfolio of board chair and directorship positions. He joined Azelis (a specialty chemicals distributor listed on Euronext Brussels) as a non-executive director and Chair in 2024. He joined the Hims & Hers Health board in July 2024. And he serves as Chairman of the restructured SAS airline board, as confirmed in SAS corporate announcements. These roles carry director remuneration and equity grants rather than executive salary packages, so his active income is now considerably lower than during his Teva years, though the wealth accumulated during that period remains.
Business holdings, ownership, and what's actually documented
Three company relationships produce verifiable public holding data for Schultz as of mid-2026.
| Company | Role | Holding Evidence | Primary Public Source |
|---|---|---|---|
| Teva Pharmaceutical (TEVA) | Former President & CEO | Equity grants and ownership per DEF 14A filings; residual TEVA shares reported in insider aggregator data | SEC DEF 14A; Benzinga insider data |
| Hims & Hers Health (HIMS) | Board Director (from July 2024) | RSU grants per director compensation policy; Form 4 filings on file with SEC | SEC 8-K; Form 4 XML filing |
| Azelis Group (AZE:Euronext) | Non-Executive Chair (from 2024) | Share holdings per year-end table in Azelis Integrated Report; director remuneration in EUR disclosed | Azelis Integrated Report 2024 and 2025 PDFs |
| SAS | Board Chairman | Directorship confirmed in corporate announcement; compensation per board remuneration policy | SAS FY 2024 Annual Report; SAS board announcement PDF |
| IFF (International Flavors & Fragrances) | Prior directorship (referenced by Benzinga) | Shares cited as component of Benzinga's reported-share estimate | Benzinga insider trades page |
The Azelis Integrated Reports for 2024 and 2025 are particularly useful because they publish a table showing Kåre Schultz's remuneration in euros and his share holdings as of a specific date (December 1, 2025 in the 2025 report). This is one of the few non-SEC sources that directly names a holding quantity tied to a specific date, making it useful for triangulation. The Hims & Hers Form 4 filings, accessible through SEC EDGAR, document RSU grants and any subsequent transactions, and are updated within days of any insider activity.
The estimated net worth range, and why the numbers vary so much
Three aggregators have published estimates, and they land in noticeably different places. For more detail on the reported figures, see the overall schultz net worth range and how it’s derived from disclosed holdings. Benzinga, QuiverQuant, and GuruFocus each publish different ed schultz net worth style estimates based on overlapping but not identical filings published estimates.
Benzinga estimates Schultz's net worth at approximately $28 million, based on reported shares across Teva, IFF, and Hims & Hers, with its estimate recalculated as of June 18, 2025. You may also see the same figures summarized in searches like alex schultz net worth Schultz's net worth. For those trying to understand the alex schultz net worth question, these same documented equity share totals are the main input. QuiverQuant puts the figure at at least $53. 2 million, with an update timestamp that reflects current share pricing at the moment of page load, meaning the number shifts daily.
GuruFocus also provides an insider-ownership-based figure, calculated from SEC ownership reports across named companies, though it frames the output around publicly traded equity positions rather than a comprehensive wealth figure.
The gap between $28 million and $53 million is not a sign that one source is wrong. It reflects genuine methodological differences: which companies' filings are included, how indirectly held shares (through entities or family trusts) are classified, whether shares that have vested and been sold are still counted, and how grant-date equity values are updated to current market prices. QuiverQuant's own page flags these limitations directly, noting that parsing errors, double-counting of indirectly owned shares, and filing classification issues can all affect the output.
A reasonable, defensible estimate for June 2026 sits in the $30 million to $55 million range for documented publicly traded equity. The lower bound is anchored by Benzinga's equity-only calculation; the upper bound reflects QuiverQuant's more expansive reading of insider filings.
But given the scale of Schultz's executive compensation at Teva across five years (with annual target packages in the range of $14 to $15 million), his total personal wealth including private assets, real estate, and accumulated savings could plausibly be higher than either figure suggests. Treating $50 million as a reasonable midpoint estimate is defensible, with the acknowledgment that the true number remains private.
Overall, this puts Kåre Schultz's donald schultz net worth estimate in the tens of millions, but it is still only based on documented public equity holdings.
How reliable is any of this, really
The core limitation is structural: there is no full-disclosure requirement for personal wealth for a private individual, even a public company director. If you are specifically looking for the latest estimate of Donald Schupak net worth, use the same SEC-filings-based approach and then compare multiple aggregators to see where they diverge.
SEC Form 4 filings are required to report changes in beneficial ownership of public company securities, but they do not capture private company stakes, real estate, cash, debt, or any assets outside SEC-regulated holdings. SEC Form 4 filing XML includes reporting person signatures “for Kare Schultz,” which helps demonstrate that this named individual is an authorized filer on public insider transaction reports [SEC Form 4 filings are required to report changes in beneficial ownership of public company securities](https://www. sec. gov/Archives/edgar/data/1773751/000177375125000299/xslF345X05/wk-form4_1758151469.
xml). This means every published estimate is a partial picture.
Currency timing is another factor. Teva's DEF 14A filings include shekel-to-dollar conversions based on average annual exchange rates (for example, 3.35 shekels per dollar for 2022). Azelis reports compensation in euros. If you are trying to build an aggregate USD-denominated net worth figure, exchange rate assumptions as of different dates will produce different totals. Benzinga's figure was recalculated in June 2025, not June 2026, so share price movements since then affect its accuracy today.
Equity grant structures also create timing distortions. Teva's DEF 14A disclosed grant-date fair values for long-term equity incentives. Aggregators who pull those values and apply current TEVA share prices to the implied share counts will get a different number than the original grant-date fair value, and the direction of that difference depends entirely on how TEVA stock has performed since the grant. For a company like Teva, which has been through significant financial turbulence, this is a material source of uncertainty.
How to verify or update this yourself today
If you want to build your own current-as-of-today picture, here is the practical sequence to follow.
- Start with SEC EDGAR full-text search (efts.sec.gov) and search for 'Kare Schultz' as a reporting person. Pull all Form 4 filings. Each one documents a transaction in a public company security and shows his current holdings after each trade. This is the most directly verifiable data point available.
- Pull Teva's DEF 14A from the most recent available fiscal year covering Schultz's CEO tenure (look for filings from fiscal years 2018 through 2022). The executive compensation tables disclose salary, bonus, and equity grant fair values in exact dollar figures.
- Access the Hims & Hers DEF 14A (April 26, 2024, accession 0001773751-24-000110 on EDGAR) for the director compensation policy. Cross-reference with any Form 4 filings showing RSU grants or sales.
- Download the Azelis Integrated Report 2025 PDF (published April 2025 via the Azelis investor relations page). Look for the director remuneration and share-holding table, which shows Schultz's shares held as of December 1, 2025 and his EUR remuneration for the year.
- Check SAS's FY 2024 Annual and Sustainability Report for board remuneration details tied to Schultz's Chair role.
- Apply current market prices to the share quantities you have identified across all companies (TEVA, HIMS, AZE on Euronext, and any others). Sum the resulting values to get an updated equity-based estimate.
- Cross-check against QuiverQuant and Benzinga for a sanity check, but use them as a starting reference, not a final answer. Note the timestamp on any third-party estimate and assume it is stale if it is more than a few weeks old given share price sensitivity.
One thing worth keeping in mind: Schultz's most wealth-generative years were the Teva CEO years from 2017 to 2022. His current role as a multi-company board chair generates director fees and equity grants that are meaningful but a fraction of executive CEO compensation. The wealth you are trying to estimate is mostly accumulated, not actively growing at the same rate it was during the Teva period. That context matters when reading any estimate, because the trajectory has shifted from accumulation to preservation and portfolio management.
For readers exploring the broader landscape of executive wealth in this surname category, Schultz is one of the more thoroughly documented profiles in this space, given his roles at publicly listed companies with mandatory SEC and Euronext disclosures. Other executives sharing the Schultz surname present varying degrees of documentation depending on whether their wealth is tied to public or private holdings, which shapes how precisely any estimate can be anchored.
FAQ
Why can Kåre Schultz’s net worth estimates swing so much between $28 million and $53 million?
Most of the spread comes from which public-company holdings are included, how “beneficial ownership” is interpreted (direct vs indirect holdings), and whether sold or vested shares are still counted. Different aggregators also revalue equity using different share prices and different “as-of” dates, so the same underlying filings can produce different totals.
Do SEC Form 4 filings capture Kåre Schultz’s full wealth?
No. Form 4 reports changes in beneficial ownership of public securities, but it excludes private company stakes, real estate, cash, loans, and many kinds of private investment. That means any “net worth” number based on SEC filings is best treated as an equity-only floor, not a full balance sheet.
How should I interpret estimates that are described as “updated daily” or “as of today”?
Those figures usually take an insider-owned share count from filings and then multiply it by the current market price. That produces day-to-day movement even if the share count did not change. If you want consistency, compare estimates using the same valuation date or the same market-price source.
What’s the biggest mistake people make when comparing different net worth sites?
Comparing totals without checking what each site counts. For example, some approaches include only directly held shares, while others attempt to parse indirectly held shares through entities or trusts, which can also introduce classification errors or double-counting.
If Teva stock price moved a lot after his grants, will grant-date fair value equal today’s implied value?
Not necessarily. DEF 14A often reports grant-date fair values, while later “net worth” estimates commonly revalue the implied share holdings using current prices. Depending on whether the stock rose or fell since the grant, the recalculated value can be substantially higher or lower than the grant-date figure.
How do currency conversions affect a Kåre Schultz net worth calculation?
They can affect inputs like pay components expressed in shekels and compensation reported in euros, especially when a site tries to translate historic or target equity values into USD. If two sites use different exchange-rate dates, the resulting totals can diverge even if they start from the same filings.
Are board chair and director roles likely to change his net worth much going forward?
They can add meaningful director remuneration and occasional equity, but they usually do not match the scale of CEO compensation. The article’s main point holds, most wealth accumulation likely occurred during earlier executive years, while later roles tend to be more about preserving and diversifying what he already built.
Could there be another Kåre Schultz with a different net worth?
Yes, name duplication is possible. The reliable disambiguation signals are his birth year (1961), Danish nationality, and the specific set of public-company roles and filings tied to that exact individual. If a claim does not match those identifiers, treat it as potentially a different person.
What would a “good enough” DIY check look like if I want to verify the estimate?
Start by pulling the relevant Form 4 and proxy disclosures for the specific companies connected to his board and executive history, extract share counts and any RSU or option activity, then revalue using a single clearly stated valuation date and currency convention. Also note whether the listing includes only current holdings or also transient positions that later sold.
Why might one aggregator show a much higher figure than another even if both use the same SEC filings?
They may interpret indirect ownership differently, include or exclude certain subsidiaries or reporting entities, or apply different rules for what counts as “beneficially owned.” Some also use parsing logic that can misclassify entities or miss filings, which can push the estimate upward or downward.
Does any estimate account for wealth in private assets like real estate?
Usually not. Unless a private-asset disclosure exists in a filing or report, most published “net worth” numbers remain equity-focused. Real estate, private investment vehicles, and personal debts are typically invisible to SEC-based methods, so the true total can be higher or lower than the public-equity total.
Next Article
Don Schultz Songwriter Net Worth: How to Verify It
Learn how to verify Don Schultz songwriter net worth using credits, royalties, and reputable financial sources, not gues
